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Historically, many different therapies have been assessed for their ability to alter disease progression of the Neuronal Ceroid Lipofuscinoses
(NCLs). While some treatments have lead to minor improvements, none have been able to arrest disease progression or improve the quality or
duration of life. Presently, many new therapeutic strategies, such as chaperone therapy, enzyme replacement therapy, gene therapy, and stem cell
therapy, are being investigated for their ability to alter the disease course of the NCLs. This review summarizes previous studied therapies,
discusses those currently being evaluated and examines possibilities for future therapies for the treatment of patients with NCL.
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The NCLs are a family of genetically inherited metabolic
storage diseases that exhibit a common pathology, lysosomal
accumulation of autofluorescent lipopigment, neurodegenera-
tion and premature death. All but one form of NCL is inherited
in an autosomal recessive manner and mutations in at least
seven genes, CLN1, CLN2, CLN3, CLN5, CLN6, CLN8 and
CTSD (cathepsin D) [1] are known to result in human disease.
Two additional genes, CLN4 [2] and CLN9 [3,4], are currently
postulated to result in the human disease, but have not yet been
identified. Additionally, animal models have revealed that
mutations in either Ctsf (cathepsin F) [5], Clcn-3 [6] or Clcn-7
[7] result in an NCL-like phenotype, but mutations within these
genes have not yet been reported in human disease.
Historically, the NCLs were classified by ‘age of disease
onset’, as infantile NCL (INCL), late infantile NCL (LINCL),
juvenile NCL (JNCL) or adult NCL (ANCL). Following the
advent of molecular biology, these ‘age of disease onset’
categories were found to typically associate with specific gene⁎ Corresponding author. Tel.: +1 7737026430; fax: +1 7737029234.
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doi:10.1016/j.bbadis.2006.08.004defects. For instance, mutations in CLN1 usually result in
infantile onset between 6 and 24 months of age, mutations in
CLN2 result in late infantile onset between 2 and 8 years of
age, and mutations in CLN3 result in juvenile onset between 4
and 10 years. However, this correlation between age of onset
and gene defect is not absolute, as several other variant forms
have been identified including variant late infantile (vLINCL,
CLN6 deficiency), Finnish variant late infantile (fLINCL,
CLN5 deficiency), Turkish variant (tLINCL, CLN8 deficiency)
and northern epilepsy/progressive epilepsy with mental retarda-
tion (NE, EPMR CLN8 deficiency).
Of the six CLN proteins that have been identified, only the
functions of palmitoyl protein thioesterase-1 (PPT-1, gene
product of CLN1) and tripeptidyl-peptidase-1 (TPP-1, gene
product of CLN2) have been described. PPT-1 and TPP-1 are
soluble lysosomal hydrolases hypothesized to function in the
degradation of macromolecules [8]. TPP-1 has been shown to
function in the degradation of mitochondrial ATP synthase
subunit c [9], however, in vivo substrate(s) of PPT-1 have not
yet been identified. The remaining four proteins, CLN3, CLN5,
CLN6 and CLN8, are transmembrane proteins of unknown
function that have been localized to multiple intracellular
locations such as ER (CLN6), ER-Golgi (CLN8), and the
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ment of patients with NCL will require the determination of
each individual's gene defect, and elucidation of each proteins
function.
This review is subdivided into six main areas: (1) Generalized
care; (2) Dietary supplements; (3) Targeted small molecules; (4)
Enzyme replacement; (5) Stem cell therapies; (6) Gene therapies.
2. Generalized care
Since no specific therapies exist for the treatment of NCL,
patient care is focused on minimizing symptoms, including but
not limited to seizures, behavioral problems, and depression.
Anticonvulsant medications are a mainstay of therapy for the
majority of NCL patients, however, increases in seizure activity
and clinical decline have been observed in patients treated with
Phenytoin (Dilantin) and Carbamazepine (Tegretol), signifying
the need for careful selection of patient medication [10–12]. As
their disease progresses patients with JNCL often suffer from
depression, and have been successfully treated using drugs such
as diazepam, haloperidol, and lithium [13]. Additionally,
physical and occupational therapy have been employed to aid
in the retention of physical abilities.
3. Dietary supplements
Antioxidant supplementation for the treatment of NCL was
investigated following observations that NCL patient derived
granulocytes had reduced peroxidase activity when measured
using the substrate p-phenylenediamene [14,15], and more
specifically, patient derived erythrocytes exhibited decreased
glutathione peroxidase activity which was corrected by
supplementation with selenium [16]. Glutathione peroxidase,
a selenium containing enzyme responsible for the destruction
of peroxides, functions in the context of other cellular
antioxidant defenses, such as vitamins A, C, E, catalase and
superoxide dismutase to protect cellular lipids and proteins
from oxidative damage [17]. These findings, in combination
with the identification of lipid peroxides within the autofluor-
escent storage material, suggested that NCL patients might be
impaired in their ability to protect cellular lipids from oxidative
damage and provided a foundation for the investigation of
antioxidant therapies for the treatment of NCL. During the mid
1970’s and through the 1980s therapeutic trials were performed
on patients with JNCL to determine the efficacy of
supplementing patients with antioxidants, including one or
more of the following, vitamin C, vitamin E, methionine, BHT,
B2, B6 and sodium selenite. The general findings of these
studies demonstrated that antioxidant treatment of JNCL
patients seemed to slow, but not stop, disease progression
[18,19]. Interestingly, measurement of peroxidase activity
using alternative substrates to p-phenylenediamene demon-
strated variable results [20–22] indicating that peroxidase
deficiency is not a primary defect in NCL. Despite the fact that
there is currently no convincing evidence for peroxidase
deficiency, antioxidant therapy is still commonly used in the
treatment of NCL patients.Further examination of JNCL patient derived erythrocytes
and serum revealed reductions in erythrocyte membrane
polyunsaturated fatty acids (PUFAs) and serum prebetalipopro-
tein [23]. In an attempt to normalize PUFAs in erythrocyte
membranes, patients were supplemented with fish oil extracts.
After 1 year of supplementation, omega-3 fatty acids were
significantly increased in patient erythrocyte membranes,
however, clinical, psychometrical, and neurophysiological
assessments, of these patients post treatment revealed no
significant changes [23]. Data collected from a subsequent
study (which evaluated intelligence, fine motor function and
vision) involving six patients suggested that supplementation of
PUFAs may arrest JNCL if early treatment is initiated and
recommended a larger study be conducted [24]. However, no
follow up studies have been reported.
Analysis of autofluorescent storage material isolated from
LINCL and JNCL patients revealed accumulation of mitochon-
drial ATP synthase subunit c, as well as proteins containing
trimethyllysine residues [25]. Storage of trimethyllysine, a
known biosynthetic precursor of carnitine, was hypothesized to
result from an inability to synthesize endogenous carnitine. This
information coupled with the identification of reduced plasma
carnitine levels in JNCL patient plasma [25] along with reported
partial deficiencies of fatty acid oxidation in patient fibroblasts
[26] led to experiments involving carnitine supplementation. In
independent studies the effects of carnitine supplementation
were studied on both mnd mice (CLN6) [27] and English Setter
dogs (CLN8) [28]. Supplementation of mnd mice with carnitine
resulted in a reduction in the amount of stored material, and
prolonged their lifespan. The dogs also demonstrated an
increase in longevity, and exhibited delays in their rate of
cognitive deterioration. Unfortunately, none of the dietary
therapies attempted for NCL have approached the apparent
success of Lorenzo's Oil, glyceryl trioleate-trierucate, for
adrenoleukodystrophy [29,30] or phenylalanine restriction for
phenylketonuria. Therefore, a better understanding of the
molecular metabolic basis of Battens disease is required before
an effective dietary therapy could be designed.
4. Targeted small molecules
4.1. Chemical chaperone therapy
Abnormalities in protein folding underlie the pathogenesis of
many neurodegenerative diseases such as Huntington's and
Alzheimer's. Normally, newly synthesized proteins obtain their
functional three-dimensional conformation by folding into their
most thermodynamically stable state, often with the help of
chaperone proteins [31]. Missense mutations often result in
misfolded proteins, by altering the thermodynamic stability of
the folded peptide which subsequently results in a reduction or
loss of enzymatic activity. Modest increases in enzyme activity
are typically associated with a reduction in disease severity,
therefore, strategies to enhance the endogenous activity of
misfolded proteins are being actively investigated. Although
counterintuitive, recent in vitro studies have demonstrated that
the addition of low molecular weight compounds, such as
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ment of mutant enzyme activities. This increase in enzyme
activity has been attributed to inhibitors and/or substrates acting
as a scaffold on which the mutant protein can be stabilized and
restructured Fig. 1.
This type of therapy, known as chemical chaperone therapy,
has been successful in the treatment of three different lysosomal
storage diseases (LSDs), Fabry Disease, Gaucher disease, and
GM-1 gangliosidosis. Fabry disease results from mutations in
the gene encoding α-galactosidase A, a homodimeric lysosomal
enzyme that hydrolyzes terminal α-galactosyl residues from
glycosphingolipids. Studies using Fabry disease patient derived
lymphoblasts (R301Q and Q279E) have shown that incubation
with galactose, or 1-deoxygalactonojirimycin (DNJ), a potent
inhibitor of α-galactosidase A, significantly increased enzyme
activity [32,33]. These studies were the basis for a further
investigations involving galactose treatment of a human Fabry
patient who had a cardiac variant of the disease [34]. Following
galactose infusions the patients' endogenous α-galactosidase
activity had increased from 7 to 10% of normal, and remarkably,
after treatment the patient no longer required cardiac transplan-
tation. Similar to the results observed following DNJ treatment
of Fabry lymphoblasts, treatment of Gaucher disease lympho-
blasts (β-glucosidase deficiency) with the inhibitor N-(n-nonyl)-
deoxynojirimycin at sub-inhibitory levels increased enzyme
activity to 2-fold, which was considered to be a therapeutic level
[35]. Finally, when N-octyl-4-epi-β-valienamine, an inhibitor
lysosomal β-galactosidase, was found to enhance GM1-beta-
galactosidase activity in a CNS mouse model of GM1-
gangliosidosis, suggesting that chaperone therapy could reverse
brain degeneration [36].
There is considerable enthusiasm that hydrolase inhibitors
could be used to enhance the enzymatic activities of PPT-1 and
TPP-1 containing missense mutations. However, one difficulty
lies in delivering the inhibitors to the cells interior. Inhibitors of
PPT-1 have been synthesized by replacing the palmitoyl-
cysteine thiol linkage with a non-hydrolyzable amide linkage
and retaining the VKIKK C-terminal sequence of K-Ras 4B to
facilitate membrane transport. DAP1 was the initial compound
studied, however, DAP1-ketoamide was a more potent inhibitor
of PPT-1 enzyme activity, and was readily taken up by cellsFig. 1. Chemical chaperone therapy. Missense mutations often result in production o
Introduction of small molecules, whose structure mimics an enzymes natural substrate
molecules, known as chemical chaperons, provide a structure on which an enzymewhen solubilized with albumin [37]. It is possible that the
lysine-rich peptide also facilitates this uptake and may be a
crucial part of the drug's bio-activity following transport across
the blood–brain barrier. Treatment of fibroblasts from a juvenile
onset INCL patient containing G108R mutation, resulted in an
almost 5-fold increase in PPT-1 activity when treated with
DAP1-ketoamide (ACG-(Dap-α-keto-hexadecanoyl)-VKIKK-
amide) (Dawson Lab, unpublished data).
It is clear that chaperone therapy will only be effective for
treatment of patients who harbor missense mutations that are not
present in the enzymes active site, and therefore, will not be a
benefit to all individuals. However, one advantage to chaperone
therapy is that the method could be used to correct the
misfolding of both soluble and membrane bound proteins, and
therefore, has the potential to be useful in the treatment of PPT-
1, TPP-1, CLN3, CLN5, CLN6, CLN8 and cathepsin D defi-
ciencies resulting from missense mutations.
4.2. Small molecule therapy for INCL and LINCL
One of the hallmarks of NCL is the accumulation of
lysosomal storage material, as such, one target of therapy has
been the removal of this material. INCL is known to result from
a deficiency of PPT-1, an enzyme that cleaves palmitoyl-
cysteine linkages. Treatment of PPT-1 deficient lymphoblasts
with high concentrations of thiols, such as N-acetylcysteine and
cysteamine, have been reported to reduce the amount of
previously stored and newly accumulated lysosomal “ceroid”
[38]. These drugs exert their effects through nucleophilic attack
of palmitoyl-cysteine linkage, however, data from an on-going
clinical trial to evaluate the effectiveness of phosphocysteamine
treatment of INCL patients are not encouraging. Additionally,
recently reported studies on cysteamine treated PPT deficient
lymphoblastoid cell lines indicate that while cysteamine was
able to decrease substrate accumulation, storage of saposins A
and D was actually increased [39].
In addition to INCL, small molecule therapy has also been
investigated for the treatment of LINCL. TPP-1 enzyme
activity was restored, up to 7% of normal, in patient derived
fibroblasts harboring nonsense mutation by exploiting the
ability of the aminoglycoside antibiotic, gentamicin, tof mis-folded proteins which, subsequently leads to a lack of enzymatic activity.
, have been shown to result in an enhancement of enzymatic activity. These small
may be re-folded to produce an enzymatically active protein.
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widely accepted that small increases in residual enzyme
activity can significantly alter disease progression, considering
that approximately half of LINCL patients harbor nonsense
mutations [40] these findings underscore the importance of
continued work in the development of small molecule therapy
in both LINCL and INCL.
4.3. Substrate reduction therapy
Several metabolic diseases, such as the glycosphingolipi-
doses, have responded positively to methods designed to
eliminate or reduce the accumulation of specific enzymatic
substrates. For example, N-butyldeoxynojirimycin, an inhibitor
of the first step in glycosphingolipid (GSL) biosynthesis, has
been used to reduce GSL accumulation and result in clinical
improvements, in both animals and humans with GSL storage
disorders [41]. It is likely that substrate reduction therapy could
be used in conjunction with other therapies, such as enzyme
replacement therapy, to enhance their effects. Substrate
reduction therapy could be a potential treatment for the NCLs,
but only after the actual substrate(s) of PPT-1 has (have) been
determined, and the functions of CLN3, 5, 6, and 8 have been
described.
5. Enzyme replacement therapy
5.1. Systemic enzyme replacement therapy
Gaucher disease (glucocerebrosidase deficiency) was the
first LSD to be successfully treated using enzyme replacement
therapy (ERT). However, while ERT was successful in
ameliorating the non-neurological symptoms present in patients
with Type 1 and Type 3 Gaucher, it was unable to stop disease
progression in the CNS seen in Type 2 and Type 3 [42,43]. The
failure of ERT to alter disease progression in the CNS illustrates
a recurring problem with the treatment of LSDs, the inability of
systemically delivered enzyme to traverse the blood–brain
barrier in therapeutic quantities.
Because of the success of ERT in the treatment of Gaucher
and other LSDs, and because PPT-1 deficiency (INCL) and
TPP-1 deficiency (LINCL) are similar to other monogenetic
disorders resulting in LSDs, ERT feasibility was investigated
for the treatment of TPP-1 deficiency. The proenzyme form of
TPP-1 protein, was expressed in Chinese-hamster ovary cells
(CHO), purified and studied. TPP-1 deficient patient derived
fibroblasts and cultured rat neurons were capable of taking up
exogenous TPP-1 protein [44]. Notably, TPP-1 deficient
fibroblasts showed a reduction in subunit c content by western
blot analysis indicating the enzyme was able to functionally
degrade its substrate [44]. Thus, if the problem of the blood–
brain barrier could be overcome, there is potential for ERT in
treatment of INCL, LINCL and cathepsin D deficiency.
One potential drawback to ERT in the context of the NCLs is
that ERT is only effective for treatment of disorders involving
soluble proteins. This would limit the use of ERT to treatment of
PPT-1 (INCL), TPP-1 (LINCL) and cathepsin D deficiency,since the other CLN proteins 3,5,6 and 8 are all membrane
bound proteins. Additionally, to prevent disease from reoccur-
ring, ERT needs to be continued throughout life.
5.2. Convection-enhanced delivery of proteins in solution
As previously mentioned, systemic ERT is unable to correct
LSD affecting the CNS, due to the inability of soluble protein to
cross the blood–brain barrier. Likewise, viral mediated gene
therapy is ineffective at distributing enzyme to all brain regions
in humans, due to the sheer size of the human brain. In an
attempt to overcome these complications, an alternative
method, convection perfusion, was studied in both rats and
primates for the ability to deliver glucocerebrosidase for the
treatment of neuronopathic Gaucher Disease [45]. Recombinant
M-6-P modified glucocerebrosidase was continually infused
into primate brain at the rate of 1–2μl per minute over a period
of 48 h using a microinfusion pump. MRI studies performed
during enzyme infusion, indicate that the infused material
gradually filled the white matter tracts of the brain. Forty-eight
hours after infusion, animals were sacrificed and their brains
were harvested for histological and enzymatic analysis.
Glucocerebrosidase immunohistochemistry on primate brain
sections was supportive of MRI studies, which demonstrated
increased cytoplasmic staining in the perfused brain region.
Analogously, enzymatic analysis of glucocerebrosidase activity
was increased in the perfused brain region, compared to the un-
infused hemisphere. This study demonstrated that convection
perfusion is able to deliver a lysosomal enzyme to a large region
of brain. However the procedure is not without drawbacks, as
with systemic ERT, convection perfusion is only effective for
treatment of disorders involving soluble proteins thus, limiting
its use to treatment of PPT-1 (INCL), TPP-1 (LINCL) and
cathepsin D deficiency. Also like systemic ERT, convection
perfusion, would require regular treatments for the duration of
life to be effective, and would be costly and invasive. However,
it is an exciting new advance for the delivery of drugs and
proteins to the CNS.
6. Stem cell therapy
6.1. Hematopoietic stem cell transplant
Hematopoietic stem cell transplant (SCT), formally referred
to as bone marrow transplant (BMT), has been successfully
used to slow disease progression and to improve the quality and
duration of life in lysosomal storage diseases affecting visceral
organs, such as mucopolysaccharidosis type 1 [46]. (For sim-
plicity, throughout the remainder of this section BMT will be
referred to as SCT.) However, it is rarely are able to completely
reverse clinical symptoms [41]. SCT effectiveness lies in its
ability to provide monocytes to multiple organs that are able to
produce and secrete an enzyme lacking in the host, thereby
reversing the deficit [41]. Because SCT relies on the secretion of
enzymes to correct a deficit, it is only appropriate for the
treatment of soluble enzyme deficiencies, as membrane bound
proteins would not be secreted. In addition to correcting
Fig. 2. Viral mediated gene therapy. Retroviral vectors are used to deliver a
normal copy of the defective gene to neuronal tissue. The normal gene encoded
by the viral vector results in protein synthesis and secretion. Surrounding cells
internalize the secreted protein through receptor-mediated endocytosis and
deliver in to the endosomal–lysosomal system.
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the inflammatory response, a common pathological factor in
many LSDs [47]. Cells of donor origin have been found in brain
tissue [48], however, depending on the individual disorder, they
may not present in sufficient quantities to correct the deficit, and
therefore, may not be universally helpful for the treatment of all
LSDs affecting the nervous system. Disadvantages to SCT
include high mortality when done in early infancy, immunolo-
gic complications.
To determine if SCT would be an appropriate treatment for
NCL, the effectiveness of SCT has been evaluated for treatment
of four different forms of NCL: canine ceroid lipofuscinosis
(CCL), INCL, LINCL and JNCL. The effectiveness of SCTwas
initially investigated for the treatment of CCL. The findings of
this study indicated that SCTwas not beneficial in the treatment
of CCL [49]. Following this original study, in 1997, two human
patients, one with LINCL and the other with JNCL, underwent
SCT [50], but the course of disease was not significantly altered.
Next, the effectiveness of SCT for the treatment of INCL was
evaluated in three individuals [51]. While SCT was able to
normalize PPT-1 activity in leukocytes of all three patients, and
seemed to delay the typical rapid deterioration associated with
INCL, SCT was unable to reverse the typical brain atrophy or
pathological changes observed in INCL. SCTwas most recently
evaluated for treatment of LINCL in one patient with advanced
disease [52]. The patient showed no improvements in TPP-1
enzyme activity or disease progression, but it was not clear if
this was due to a poor engraftment of donor cells (only 10–
20%). From the results reported in these four studies, it appears
that under these conditions SCT is not an effective treatment for
the NCLs.
However, research is currently on-going to enhance effec-
tiveness of SCT by exploiting the ability of particular reagents
to reversibly alter the permeability of the blood–brain barrier.
Recently reported work has demonstrated that intravenous
treatment of newborn mice with vasoendothelial growth factor
(VEGF) resulted in enhanced permeability of the blood–brain
barrier to both proteins and viral vectors [53]. Newborn mice
affected with the LSD, globoid cell leukodystrophy (MPS VII),
were treated with VEGF prior to administration of lentiviral
vector encoding β-glucuronidsase. Mice who received VEGF
treatment prior to lentivirus administration demonstrated a
significant increase in lifespan when compared to control
animals. Therefore, if techniques could be developed to
permeabilize the blood–brain barrier, stem cell therapy could
be a potentially useful strategy for treatment of INCL, LINCL
and cathepsin D deficiency.
6.2. Umbilical-cord blood
Umbilical-cord blood stem cell therapy has been studied for
the treatment of Infantile Krabbe Disease. Also known as globoid
cell leukodystrophy, Krabbe disease is an autosomal recessive
hypomyelinating disease, resulting from a deficiency of the
lysosomal enzyme galactocerebrosidase. Transplantation of
unrelated, normal umbilical-cord blood cells into both pre- and
post-symptomatic infants with Krabbe disease was performed.Significant neurological improvements were observed in patients
who received transplants pre-symptomatically, but not in patients
who received them post-symptomatically [54]. This study
provides hope of another possible type of therapy for individuals
with NCL. However, to be effective this therapy requires early
diagnosis, preferably at birth or prenatally.
6.3. Neural stem cell therapy
Clinical trials to evaluate the safety and ability of human fetal
central nervous system stem cells (HuCNS-SC) to affect disease
progression of INCL (PPT-1 deficiency) and LINCL (TPP-1
deficiency) are currently being proposed. Participants in this
proposed study must have loss of function mutations and will be
monitored for a minimum of 5 years post transplantation. The
project is based on preliminary data obtained from an INCL
mouse model in which human neurons were observed in the
mouse CNS following embryonic human neural cell transplan-
tation. Potential problems with this type of therapy include the
need for concomitant immunosuppressive therapy, the failure of
cells to migrate into all brain regions and the possibility of
tumor formation.
7. Gene therapy
7.1. Direct CNS vector mediated gene therapy
Viral mediated gene therapy relies on the ability of viruses to
infect host cells and hijack the host cellular machinery. Like
stem cell therapy, viral mediated gene therapy relies on a
population of cells harboring a normal copy of a gene to over-
produce and secrete a protein to complement the neighboring
deficient cells. Fig. 2. Transduction of terminally differentiated
cells has been successfully achieved in vivo in LSD animal
models by injection of viral based vectors directly into the brain,
negating the complications of the blood–brain barrier [55].
Unilateral injection of recombinant feline immunodeficiency
virus, genetically modified to contain β-glucuronidase gene,
into adult mucopolysaccharidosis type VII (MPS VII) mice
resulted in both an improvement in cellular pathology, and a
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is of great significance because it demonstrated that it is
possible to reverse neurological damage in LSD brain. This is
critical for treatment of NCL patients, as most patients typically
sustain significant damage by the time of diagnosis.
Recently, studies have been conducted in mouse models to
determine the effectiveness of direct CNS and ocular vector
mediated gene therapy for treatment of INCL and LINCL.
7.2. INCL
To evaluate the feasibility of direct CNS vector mediated
gene therapy for the treatment of INCL, Griffey and colleagues
cloned human PPT-1 cDNA into recombinant adeno-associated
virus 2 (rAAV-PPT1) and injected it into PPT-1 deficient mouse
brain [56]. This study demonstrated several positive findings
such as, an increase in PPT-1 enzyme activity in brain areas
adjacent to the injection sites, coupled with a corresponding
reduction in autofluorescent lipopigment accumulation. In
addition, a reduction in the activity of β-glucuronidase was
found in one of the two injection areas, suggesting a reduction
in the non-specific elevation of lysosomal enzymes associated
with many LSDs. Brain weights and cortical thickness of mice
transduced with rAAV-PPT1 were increased when compared to
PPT-1 deficient mice, an important finding as INCL is
associated with significant brain atrophy. A subsequent study
by the same group, established that functional improvements,
assessed by a series of behavioral tests, were directly related to
the number of injections the mice received [57]. Confirmatory
of their previous findings, treated animals showed a reduction in
autofluorescent storage material, more normal brain histology,
and increased brain mass when compared to untreated PPT-1
deficient mice. Unfortunately, despite improvements in brain
architecture, there was no corresponding reduction in seizure
activity or increase in the life span of treated mice when
compared to untreated mice.
In a subsequent study designed to examine the effects of
gene therapy on ocular associated pathology, the AAV-PPT1
vector was injected intravitreally in PPT-1 deficient mice [58].
Measurement of whole eye PPT-1 activity demonstrated a five-
fold increase in PPT-1 activity in AAV-PPT1 treated PPT-1
deficient mice when compared to untreated controls and
significant improvements were also observed in both retinal
function and ocular histology of treated mice. PPT-1 deficient
mice which received AAV-PPT1 injections, exhibited activity of
PPT-1 in brain regions corresponding to areas containing the
important structures of the brain visual system. Notably,
neurodegeneration typically associated with the INCL mouse
brain visual system was also reduced.
7.3. LINCL
To determine the viability of viral-mediated delivery of TPP-
1 to mouse brain, TPP-1 cDNA was cloned into three different
viral vectors, recombinant adenovirus (AV), feline immunode-
ficiency virus (FIV) and adeno-associated virus (AAV) [59].
TPP-1 activity was increased 3–7 fold of normal, in hemi-spheres receiving injections from any one of the three vector
constructs. This study demonstrated the viability of direct CNS
viral-mediated gene therapy as a treatment for LINCL.
The effects of viral-mediated delivery of TPP-1 to rodent and
non-human primate brains were studied by Sondi and
colleagues using adeno-associated virus-2 (AAV-2) [60]. They
established that long-lasting TPP-1 expression, resulting from
viral transduction, was detectible in brain neurons by
immunohistochemistry at time points greater than 18 months
post injection in rats. In addition to rodent studies, African green
monkeys were also evaluated, as their large brain size is more
similar to the human brain. Monkeys received 12 injections of
virus, and were sacrificed at either 5 or 13 weeks following
injection. Immunohistochemisty done on primate samples from
both time points revealed that TPP-1 expression in neurons was
extensive. This study demonstrated that viral-mediated gene
therapy could result in expression of protein throughout the
large volume of the primate brain.
Two different adeno-associated virus (AAV) vectors contain-
ing human TPP-1 cDNA were evaluated for their ability to
reduce the pathology in a murine model of LINCL. Six-week-
old, TPP-1 deficient mice received intracranial injections of
either AAV2CUhCLN2 or AAV5CUhCLN2 vector containing
TPP1 cDNA. The AAV5CUhCLN2 vector was more efficient at
transduction of neurons than AAV2CUhCLN2, but injection of
either vector resulted in increased TPP-1 activity near the
injection site and a corresponding decrease in the amount of
stored autofluorescent lipopigment and curvilinear structures
[61].
Cornell University's Institute of Genetic Medicine has
investigated the feasibility of gene transfer therapy for the
treatment on LINCL. The human trials have commenced in
2005 and the results are awaited [62].
In conclusion, these studies have demonstrated clear proof of
principal that direct CNS vector mediated gene therapy results in
pathological improvements in murine models of both INCL and
LINCL, suggesting that direct CNS vector mediated gene
therapy may be helpful in the treatment of human INCL and
LINCL. However, while direct CNS vector mediated gene
therapy has worked well for the treatment of LSD in mice, the
complications of human brain size and immune responses
require careful consideration before this is a viable treatment
option for humans. Identification of viral vectors with reduced
antigenicity, increased potency, and whose long-term expression
could be controlled by an inducible promoter would be welcome
advancements in the development of direct vector mediated gene
therapy for NCL and other LSDs affecting the CNS.
7.4. Genetically modified cell therapy
Genetically modified cell therapy (GMCT) is similar to stem
cell therapy, but with several advantages. Because GMCT
utilizes a patient's own cells, and not embryonic stem cells, it
circumvents two common problems of conventional stem cell
therapy, namely, immunologic complications and ethical
concerns. Neonatal mucopolysaccharidosis type VII (MPS
VII, Sly syndrome) mice received lateral ventrical transplants
Fig. 3. Summary of therapeutic options for NCL gene defects.
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with the human beta-glucuronidase gene. The results of this
study demonstrated that transplantation of bone marrow stromal
cells overexpressing human beta-glucuronidase corrected the
pathology associated with MPS VII [63]. This technique is
advantageous in that bone marrow stromal cells are readily
available from patient bone marrow, they are easy to grow in
culture, and they can be directly injected into the central
nervous system, avoiding the complication of crossing the
blood–brain barrier [63]. As previously mentioned, they
eliminate the immunological complications associated with
donor cells, and ethical concerns of using embryonic stem cells
[63]. The main confounding factor in this study is that these
mice received transplants neonatally, while most individuals
with NCL are not diagnosed until disease progression has
already become pronounced. Perhaps with the expansion of
newborn screening to include all lysosomal storage diseases,
this type of treatment would be feasible.
8. Conclusions
In summary, several promising new types of therapies are
being investigated for the treatment of the Neuronal Ceroid
Lipofuscinoses including, chaperone therapy, stem cell therapy
and CNS vector mediated gene therapy. Fig. 3. However, there
is a resounding need for earlier and more rapid diagnosis ofNCL, as significant damage occurs between onset of initial
symptoms and diagnosis. Ideally, the near future will allow us to
elucidate the common thread uniting the Neuronal Ceroid
Lipofuscinoses, and with the development of new therapies and
expansion of newborn screening we will be able to identify and
treat individuals before disease progression occurs.
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